<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01263821</url>
  </required_header>
  <id_info>
    <org_study_id>09-0069</org_study_id>
    <nct_id>NCT01263821</nct_id>
  </id_info>
  <brief_title>Image Guided Therapy in the Treatment of Gliomas</brief_title>
  <official_title>Image Guided Adaptive Multi-modality Therapy in the Treatment of Gliomas</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>New York University School of Medicine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>New York University School of Medicine</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: New imaging techniques using magnetic resonance imaging give better tumor
      definition, thus may lead to better tumor targeting and avoid damaging critical parts of
      normal brain.

      PURPOSE: This phase I/II trial is studying how well image-guided therapy works in treating
      patients with newly diagnosed intracranial glioma.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVES:

      I. To correlate the imaging findings with pathological grade following surgery in patients
      with newly diagnosed intra-cranial gliomas.

      SECONDARY OBJECTIVES:

      I. To determine the feasibility of defining the optimal target volume for radiation therapy
      using MR spectroscopy, diffusion, perfusion and functional imaging. II. To monitor
      therapeutic responses following treatment using MR spectroscopy, diffusion imaging and
      perfusion study.

      III. To monitor changes in neurocognitive functioning following image guided therapy.

      OUTLINE: Patients undergo magnetic resonance spectroscopic imaging, functional magnetic
      resonance imaging (MRI), diffusion-weighted MRI, and perfusion-weighted MRI. Patients then
      undergo maximum surgical resection followed by intensity-modulated radiation therapy (IMRT) 5
      days a week for 6 weeks. After completion of study treatment, patients are followed up every
      3 months for the first year then every 6 months for another year.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Lack of enrollment
  </why_stopped>
  <start_date>August 2009</start_date>
  <completion_date type="Actual">April 2014</completion_date>
  <primary_completion_date type="Actual">April 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Feasibility of identifying low grade and high grade tumor location with imaging techniques that include MRSI,perfusion MRI, and DTI</measure>
    <time_frame>Twice a year, after enrollment of first 25 patients, and at study completion</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incorporate imaging techniques of MRSI, perfusion MRI and DTI into the radiotherapy treatment planning system for target delineation</measure>
    <time_frame>Twice a year, after enrollment of first 25 patients, and at study completion</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical efficacy of this biological image-guided treatment in gliomas</measure>
    <time_frame>Twice a year, after enrollment of first 25 patients, and at study completion</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">15</enrollment>
  <condition>Glioma</condition>
  <arm_group>
    <arm_group_label>Arm I</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients undergo magnetic resonance spectroscopic imaging, functional magnetic resonance imaging (MRI), diffusion-weighted MRI, and perfusion-weighted MRI. Patients then undergo maximum surgical resection followed by intensity-modulated radiation therapy (IMRT) 5 days a week for 6 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Diffusion-weighted magnetic resonance imaging</intervention_name>
    <description>Undergo diffusion-weighted MRI</description>
    <arm_group_label>Arm I</arm_group_label>
    <other_name>Diffusion-weighted MRI</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Perfusion-weighted magnetic resonance imaging</intervention_name>
    <description>Undergo perfusion-weighted magnetic resonance imaging</description>
    <arm_group_label>Arm I</arm_group_label>
    <other_name>Perfusion-weighted MRI</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Functional magnetic resonance imaging</intervention_name>
    <description>Undergo functional MRI</description>
    <arm_group_label>Arm I</arm_group_label>
    <other_name>fMRI, functional MRI</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Magnetic resonance spectroscopic imaging</intervention_name>
    <description>Undergo MR spectroscopic imaging</description>
    <arm_group_label>Arm I</arm_group_label>
    <other_name>1H-nuclear MRSI, Proton MRSI</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Therapeutic conventional surgery</intervention_name>
    <description>Undergo maximal surgical resection</description>
    <arm_group_label>Arm I</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Quality-of-life assessment</intervention_name>
    <description>Ancillary studies</description>
    <arm_group_label>Arm I</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Radiation therapy treatment planning/simulation</intervention_name>
    <description>Undergo IMRT planning</description>
    <arm_group_label>Arm I</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Intensity-modulated radiation therapy</intervention_name>
    <description>Undergo intensity-modulated radiation therapy</description>
    <arm_group_label>Arm I</arm_group_label>
    <other_name>IMRT</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Questionnaire administration</intervention_name>
    <description>Ancillary studies</description>
    <arm_group_label>Arm I</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histologically confirmed, newly diagnosed intracranial glioma

          -  A diagnostic contrast enhanced CT/MRI demonstrating the lesion prior to registration

          -  Karnofsky performance status &gt;= 60

          -  Ability to undergo MR imaging with the use of Gadolinium dye

          -  Patient must sign a study specific informed consent form; if the patient's mental
             status precludes his/her giving informed consent, written informed consent may be
             given by the patient's legal representative

        Exclusion Criteria:

          -  Inability to obtain histological proof of glioma

          -  Allergy to Gadolinium contrast

          -  Any condition including metallic implants or cardiac pace makers that make the
             candidate ineligible for MR imaging

          -  Any medical condition including renal or cardiac insufficiency that make the candidate
             a high risk for gadolinium contrast administration

          -  Karnofsky performance status of =&lt; 50

          -  Prior history of radiation therapy to the brain

          -  Pregnancy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>7 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Joshua Silverman, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>New York University School of Medicine</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>NYU Cancer Institute</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10016</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 16, 2010</study_first_submitted>
  <study_first_submitted_qc>December 17, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 21, 2010</study_first_posted>
  <last_update_submitted>August 3, 2017</last_update_submitted>
  <last_update_submitted_qc>August 3, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">August 4, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>glioma</keyword>
  <keyword>biologic imaging</keyword>
  <keyword>magnetic resonance spectroscopy</keyword>
  <keyword>magnetic resonance imaging</keyword>
  <keyword>perfusion imaging</keyword>
  <keyword>diffusion imaging</keyword>
  <keyword>functional magnetic resonance imaging</keyword>
  <keyword>radiation therapy</keyword>
  <keyword>intensity modulated radiation therapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glioma</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

